Introduction
Glioma is the most frequent type of primary malignant brain tumor, arising from the brain or spinal cord tissues [1] . According to the levels of malignancy, the World Health Organization (WHO) classification divides gliomas into grade I to grade IV [2] . Glioblastoma multiforme (GBM, grade IV) is the most malignant and frequent type, accounting for approximately 70% of all diagnosed gliomas [3] . The prognosis of glioma remains poor because of the characteristic malignant proliferation and diffuse invasion [4] . Therefore, a better understanding of the molecular mechanisms of the occurrence and development of glioma may provide new therapeutic target for glioma and improve the prognosis of this disease.
Gene associated with retinoid-interferon-induced mortality-19 (GRIM-19, also known as NDUFA13) was initially identified as a novel cell death-regulatory molecule in a breast carcinoma cell line by the antisense knockout technique [5] . Subsequent studies showed that GRIM-19 plays essential role in normal embryonic development, cell apoptosis, and cell growth [6] [7] [8] [9] [10] . Recent evidence has suggested that GRIM-19 may serve as a tumor suppressor protein in various human cancers. For example, GRIM-19 mutations have been detected in some thyroid carcinomas [11] . Loss of expression of GRIM-19 has been reported in renal cell carcinoma [12] , cervical cancer [13] , colon cancer [14] , and glioma [15] . Several reports have shown that GRIM-19 can negatively regulate the activity of signal transducer and activator of transcription 3 (STAT3) and the expression of STAT3 downstream genes, thus inhibiting cell transformation [9, [13] [14] [15] . It has been stated that GRIM-19 exerted inhibitory effects on cell proliferation and migration, and promotion effects on cell apoptosis of glioma cell lines.
miRNAs, small non-coding RNA molecules (approximately 20-23 nts), function in the degradation of mRNA and post-transcriptional regulation of target gene expression through binding to the 3 -UTRs of the target gene [16] . Numerous studies have revealed altered expression of miRNAs in a wide spectrum of human cancers, including glioma [17] . These researches also have established that many miRNAs can elicit oncogenic or tumor suppressor activities in various malignancies [17, 18] .
In the present study, the TargetScan algorithm was used to predict the miRNAs targetting GRIM-19, and four miRNAs were predicted to target the 3 -UTR of GRIM-19. The luciferase assay confirmed that one of the four identified miRNAs miR-6743-5p directly targetted the 3 -UTR of GRIM-19 and regulated its expression in U251 glioma cells. GRIM-19 expression level was inversely correlated to miR-6743-5p expression in glioma specimens and cell lines. Further cell proliferation and apoptosis assays showed that knockdown of the expression of GRIM-19 partially rescued the effects of miR-6743-5p inhibitor in glioma cells. Additionally, we investigated the roles of STAT3 pathway in the functions of miR-6743-5p/GRIM-19.
Materials and methods

Cell lines
The human glioma cell lines (T98G, U251, U373, U87, and SHG44) were supplied by the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). T98G, U373, and U87 were grown in Eagle's minimum essential medium (MEM; HyClone, Logan, UT, U.S.A.), while other two cells were cultured in Dulbecco's modified Eagle's medium (DMEM; HyClone). Both culture media were supplemented with 10% FBS (Gibco, Carlsbad, CA, U.S.A.) and antibiotics. All cell lines were incubated at 37
• C in a humidified atmosphere containing 5% CO 2. Transfection of the miRNA mimic, miRNA inhibitor, and siRNA
Tissues' samples
The miRNA inhibitor of hsa-miR-17-3p, hsa-miR-423-5p, hsa-miR-3184-5p and hsa-miR-6743-5p, hsa-miR-6743-5p mimic as well as miRNA inhibitor scramble (anti-miR-control) and controls of the miRNA mimic scramble (miR-control) used in our study were synthesized by Genepharm Technologies (Shanghai, China). Glioma cells at approximately 70% confluence were transfected with a final concentration of 30 nM for miRNA inhibitor or 5 nM for miRNA mimic using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, U.S.A.) in accordance with protocols suggested by the manufacturer. At 48 h post transfection, cells were harvested for RNA extraction and real-time PCR analysis.
Real-time PCR
Total RNA and miRNA was extracted from tissue samples or glioma cell lines by the TRIzol reagent (Invitrogen, Carlsbad, CA, U.S.A.). Stem-loop real-time RT-PCR was carried out to analyze miRNA expression. U6 RNA was used as an miRNA internal control. Briefly, extracted RNAs were converted into cDNAs with stem-loop reverse-transcription primers with cDNA synthesis kit (Thermo Fisher Scientific, Rockford, IL, U.S.A.). Real-time PCR was then performed using Maxima SYBR Green qPCR Master Mixes (Thermo Fisher Scientific) with miRNA or U6-specific forward primer and a universal reverse primer on ABI 7300 system (Applied Biosystems, Foster City, CA, U.S.A.) as the manufacturer suggested. The primers used here are listed in Table 1 . Real-time PCR was performed to determine the mRNA levels of interested genes. In brief, the extracted total RNA was treated with DNase I (Roche, Indianapolis, IN, U.S.A.) to remove possible genomic DNA contamination and reverse-transcribed into cDNA with cDNA synthesis kit (Thermo Fisher Scientific). GAPDH was served as an internal control for real-time PCR. The PCR primers are listed in Table 2 . Target gene expression was calculated using the 2 − C t method. 
Luciferase reporter assay
The human GRIM-19 3 -UTR carrying a wild-type (WT) or mutant (MUT) binding sequence of miR-6743-5p was inserted into the pGL3 vector (Promega, Madison, WI, U.S.A.) to make pGL3-GRIM-19-WT or pGL3-GRIM-19-MUT, respectively. The sequence of constructs was confirmed by DNA sequencing. Glioma cells were seeded into 24-well plates and co-transfected with miR-6743-5p mimic or inhibitor, and pGL3-GRIM-19-WT or pGL3-GRIM-19-MUT using Lipofectamine 2000. The luciferase activity was determined 24 h after transfection using a Dual-Glo R Luciferase assay kit (Promega), normalizing to Renilla luciferase activity.
Knockdown of GRIM-19 expression
To knock down the expression of GRIM-19, the oligonucleotides of shRNA targetting human GRIM-19 (shGRIM-19, 5 -CCGGCCATCGACTACAAACGGAATTCTCGAGGAATACCTCATCTTTCCTCTTTTTTTC-3 and 5 -AATTGAAAAAAAGAGGAAAGATGAGGTATTCCTCGAGAATT CCGTTTGTAGTCGATGGGGCCT-3 ) and control shRNA (shNC) were synthesized by Generay (Shanghai, China). The oligonucleotides were annealed and subcloned into AgeI/EcoRI sites of the lentiviral vector PLKO.1. Lentivirus was produced by transfecting HEK293T cells with the lentiviral construct and lentiviral packaging vectors with Lipofectamine 2000 based on the manufacturer's instructions. At 48 h post transfection, viruses were collected and infected glioma cells in the presence of 8 μg/ml polybrene.
Cell proliferation assay
The cell growth was determined by using a cell-counting kit (CCK)-8 (CCK-8) (Dojindo Lab, Kumamoto, Japan). Briefly, cells were seeded in 96-well plates at 5000 cells per well. Cells were transfected with indicated miRNA mimic/inhibitor, infected with shGRIM-19 or shNC lentivirus, and/or treated with 10 μM AG490 (Selleck Chemicals, Houston, TX, U.S.A.) or vehicle (DMSO) as indicated. After incubation for indicated time periods, cells were incubated with the CCK-8 reagent for 1 h and optical density (OD) values at 450 nm were determined. Triplicates were performed at each time point.
Evaluation of apoptosis by flow cytometry
The percentages of apoptotic cells were determined by Annexin V-FITC Apoptosis Detection Kit (Beyotime, Shanghai, China). Cells were seeded in six-well plates at 300000 cells per well and treated as described above. At 48 h after treatment, cells were harvested, washed with ice-cold PBS, and double-labeled with Annexin V-FITC and PI in the dark according to the protocols suggested by the manufacturer. Cells were immediately analyzed using a flow cytometer (BD Biosciences, San Jose, CA, U.S.A.).
Western blotting
Total protein was extracted by using RIPA lysis buffer, resolved on SDS/polyacrylamide gel, and transferred on to nitrocellulose membranes (Millipore, Bedford, U.S.A.). Following blocking with 5% skim milk, the membranes were probed with antibodies against GRIM-19, p-STAT3, STAT3 (Abcam, Cambridge, MA, U.S.A.), and GAPDH (Cell Signaling, Danvers, MA, U.S.A.). After incubation with the horseradish peroxidase-conjugated secondary antibody (Beyotime), the blots were developed with ECL system (Bio-Rad, Richmond, CA, U.S.A.).
Statistical analysis
Statistical analyses were conducted with GraphPad Prism software Version 6.0 (San Diego, CA, U.S.A.). Student's t test and ANOVA test were carried out to determine the statistical significance between two groups and amongst more than two groups, respectively. Pearson correlation analysis was applied to evaluate the relationship between GRIM-19 and miR-6743-5p expression. All in vitro experiments were done in triplicates and repeated at least three times. The criterion for statistical significance was set at P<0.05.
Results
GRIM-19 is targetted by miR-6743-5p
The TargetScan algorithm (targetscan.org) was applied to predict the miRNAs targetting GRIM-19. We found that hsa-miR-17-3p, hsa-miR-423-5p, hsa-miR-3184-5p, and hsa-miR-6743-5p had the potential to bind with GRIM-19. The predicted interaction between the miRNAs and the target sequence within the GRIM-19 3 -UTR is shown in Figure 1A .
To clarify whether these miRNAs could regulate GRIM-19 mRNA expression in glioma, we knocked down the expression of these miRNAs in a glioma cell line, U251, and then assessed GRIM-19 expression levels. The levels of miR-17-3p, miR-423-5p, miR-3184-5p, and miR-6743-5p dropped to 7.7, 9.1, 17.6, and 7.5% of the normal levels when the cells were treated with corresponding miRNA inhibitor, respectively ( Figure 1B) . Negative control inhibitor (anti-miR-control) had no effects on the expression of these miRNAs. As indicated by real-time PCR analysis, the GRIM-19 mRNA expression was significantly enhanced by the treatment of miR-6743-5p inhibitor (anti-miR-6743-5p), whereas inhibitors for other three miRNAs had no obvious effect on GRIM-19 expression ( Figure 1C) .
To confirm that GRIM-19 was a direct target gene of miR-6743-5p, we constructed GRIM-19 WT and MUT GRIM-19 3 -UTR luciferase reporter plasmids and performed the 3 -UTR luciferase assay. As shown in Figure  1D , the luciferase activity of WT GRIM-19 3 -UTR reporter was significantly reduced after the co-transfection of miR-6743-5p mimic in U251 cells. On the contrary, miR-6743-5p inhibitor (anti-miR-6743-5p) remarkably enhanced the luciferase activity of WT 3 -UTR reporter. The miR-6743-5p mimic or inhibitor had no effects on the luciferase activity of MUT 3 -UTR reporter. These data suggested that miR-6743-5p suppressed GRIM-19 mRNA expression by targetting the 3 -UTR.
Correlation analyses in glioma tissues and cell lines
The expression of miR-6743-5p and GRIM-19 mRNA were assessed in 15 normal brain tissues (NB) and 90 glioma tissues by real-time PCR. Decreased GRIM-19 mRNA expression (Figure 2A , P<0.001) and increased miR-6743-5p expression ( Figure 2B , P<0.01) were observed in glioma tissues as compared with normal tissues.
Pearson correlation analysis revealed a statistically significant negative correlation between the expression of GRIM-19 and miR-6743-5p in 90 glioma tissue samples ( Figure 2C ). Furthermore, an inverse correlation was also in five glioma cell lines between the expression of GRIM-19 and miR-6743-5p ( Figure 2D ). These data further supported that GRIM-19 was regulated by miR-6743-5p in glioma. 
Opposite effects of miR-6743-5p and GRIM-19 on glioma cell proliferation and apoptosis
To investigate the biological effects of miR-6743-5p/GRIM-19 in glioma, we analyzed the proliferation and apoptosis of U251 cells after miR-6743-5p inhibitor treatment or GRIM-19 knockdown. GRIM-19 expression was verified by real-time PCR analyses ( Figure 3A) . The exposure of the miR-6743-5p inhibitor decreased the proliferation rate, whereas the cells with GRIM-19 knockdown showed an increased proliferation rate ( Figure 3B) . Similarly, the percentage of apoptotic cells was significantly higher in the cells treated with the miR-6743-5p inhibitor, whereas the knockdown of GRIM-19 exhibited an inverse effect as defined by Annexin V/PI staining ( Figure 3C ) and TUNEL staining (Supplementary Figure S1) . These data indicated that miR-6743-5p and GRIM-19 had opposite effects on glioma cell proliferation and apoptosis. Furthermore, the cells treated with both the miR-6743-5p inhibitor and GRIM-19 shRNA showed significantly higher proliferation and lower apoptotic rate than the cells treated with the miR-6743-5p inhibitor only ( Figure 3B,C, D) , indicating that miR-6743-5p may induce cell proliferation and inhibit cell apoptosis by down-regulating GRIM-19.
miR-6743-5p regulates the activity of STAT3 via GRIM-19
A previous study has shown that GRIM-19 exerted functions in glioma cells partially through STAT3-dependent pathway [15] . To explore the effect of miR-6743-5p on the activity of STAT3, Western blot analyses were performed in U251 cells. The miR-6743-5p inhibitor significantly suppressed the phosphorylation of STAT3, while the knockdown of GRIM-19 had the opposite effect ( Figure 4A) . Further, we analyzed the expression of STAT3 target genes, CyclinD1 and Bcl-2, at mRNA level. The mRNA expression of CyclinD1 and Bcl-2 was inhibited by the treatment of miR-6743-5p inhibitor, but increased by GRIM-19 knockdown ( Figure 4B,C) . Additionally, when compared with cells treated with the miR-6743-5p inhibitor, the glioma cells treated with both the miR-6743-5p inhibitor and shGRIM-19 exhibited higher levels of p-STAT3 as well as mRNA levels of CyclinD1 and Bcl-2 ( Figure 4B ), indicating that miR-6743-5p may active STAT3 pathway by down-regulating GRIM-19. 
miR-6743-5p/GRIM-19 regulates glioma cell proliferation and apoptosis via STAT3 pathway
To further confirm the involvement of STAT3 in the functions of miR-6743-5p/GRIM-19, a STAT3 inhibitor AG490 was used. AG490 exposure in U251 cells had no effects on the mRNA and protein expression of GRIM-19 ( Figure  5A,B) , but significantly decreased the p-STAT3, and the mRNA expression of CyclinD1 and Bcl-2 ( Figure 5B,C) . Overexpression of miR-6743-5p or GRIM-19 knockdown activated STAT3 pathway, which was notably suppressed by AG490 treatment (Figure 5B,C) . Consistently, AG490 exposure partially rescued the proliferation-promoting and anti-apoptosis effects of miR-6743-5p overexpression or GRIM-19 knockdown ( Figure 5D ,E and Supplementary Figure S2 ). These data indicated that miR-6743-5p/GRIM-19 regulated the proliferation and apoptosis of glioma cells through regulating STAT3 activity.
Discussion
GRIM-19 was first identified by Angell et al. [5] as a novel cell death-regulatory molecule. Since its identification, GRIM-19 is considered to actively function in embryonic development, cell growth, and apoptosis [6] [7] [8] [9] [10] . Besides, it may exert tumor-suppressive role in human cancers [11] [12] [13] [14] . The present study focussed on the regulation of GRIM-19 expression in glioma. To the best of our knowledge, there are three major findings of the present study that have not been reported. First, we have shown for the first time that miR-6743-5p directly targetted GRIM-19 and down-regulated its expression in glioma cells. Second, the suppression of miR-6743-5p caused a significant inhibition of cell proliferation and a marked induction of cell apoptosis in glioma cells, and this phenotype was rescued by GRIM-19 knockdown. Last, treatment with STAT3 inhibitor AG490 partially rescued the proliferation-promoting and anti-apoptosis effects of miR-6743-5p overexpression or GRIM-19 knockdown. Aberrant expression of hundreds of miRNAs has been reported in GBM tissues [17] . A number of miRNAs, such as miR-9 [19] , miR-21 [20] , miR-125b [21] , and miR-221/222 [22] , play important roles in the progression and development of glioma via repressing the expression of tumor suppressor genes. Considering the post-transcriptional regulatory role of miRNAs, we supposed that miRNAs may be involved in GRIM-19 regulation. By bioinformatics tools, we predict several miRNAs that targetted GRIM-19. Then, by specific miRNA inhibitor transfection and luciferase assays, we demonstrated that miR-6743-5p, a miRNA with unknown function, directly bound to the 3 -UTR of GRIM-19, thus reducing the mRNA and protein levels of GRIM-19 ( Figure 1) . miR-6743-5p was observed to be up-regulated in human glioma tissues compared with normal brain tissues. The lower expression of GRIM-19 in glioma tissues was consistent with the previous study [15] . Moreover, an inverse correlation between the expression of miR-6743-5p and GRIM-19 was observed in glioma tissues and cell lines (Figure 2) . Furthermore, the inhibition of miR-6743-5p expression suppressed the proliferation and induced apoptosis of U251 glioma cells (Figure 3) , while miR-6743-5p mimic had the inversed effects ( Figure 5 ). In addition, knockdown of GRIM-19 expression could reverse the effects of miR-6743-5p inhibitor (Figure 3 ), suggesting that miR-6743-5p exerts oncogenic function via targetting GRIM-19.
STAT3 plays a critical role in cell growth, anti-apoptosis, and cell differentiation. It is a tumor suppressor and constitutively active in glioma [23, 24] . A previous study has reported that p-STAT3 expression is inversely correlated to GRIM-19 expression in gliomas and that GRIM-19 negatively regulates STAT3 activity in glioma cells [13] . Here, the inhibition of miR-6743-5p expression suppressed the phosphorylation of STAT3, and the mRNA expression of CyclinD1 and Bcl-2, two target genes of STAT3 (Figure 4) , while miR-6743-5p mimic had the inversed effects ( Figure  5) . Furthermore, GRIM-19 knockdown could rescue the effects of miR-6743-5p inhibitor on STAT3 (Figure 4) . The exposure of STAT3 inhibitor AG490 could partially abolish the proliferation-promoting and anti-apoptosis effects of miR-6743-5p overexpression or GRIM-19 knockdown ( Figure 5 ). These findings suggested that STAT3 was involved in the functions of miR-6743-5p/GRIM-19 in glioma.
In conclusion, the current study explored the molecular mechanisms accounting for the dysregulation of GRIM-19 in glioma cells and identified that miR-6743-5p directly targetted GRIM-19. Furthermore, miR-6743-5p plays an essential role in the proliferation and apoptosis of glioma cells through modulating GRIM-19/STAT3. 
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